Lakewood-Amedex Biotherapeutics Inc. Common Stock
NASDAQ: LABT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kelvin Cooper
- Employees
- 5
- Headquarters
- University Park, United States
- IPO year
- 2026
- Market cap
- $1.6M
- Website
- http://www.lakewoodamedex.com
Loading LABT…
Loading profile data…Frequently asked questions about LABT
What does Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) do?
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Br...
Where does LABT trade?
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) trades on the NASDAQ Global Market.
What sector is LABT in?
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lakewood-Amedex Biotherapeutics Inc. Common Stock?
Kelvin Cooper is the chief executive officer of Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT).
Where is Lakewood-Amedex Biotherapeutics Inc. Common Stock headquartered?
Lakewood-Amedex Biotherapeutics Inc. Common Stock is headquartered in United States.
Does LABT pay a dividend?
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LABT go public?
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) completed its initial public offering in 2026.